Study Objective: ECD patients with vemurafenib treatment seem to have a stable disease. This study evaluates the possibility of treatment interruption. Other BRAF inhibitors, such as dabrafenib, have recently been proposed for treating BRAF mutated histiocytoses. Other BRAF inhibitor interruption treatment should also be prospectively evaluated.
Principal Investigator: Julien Haroche, M.D., Ph.D., HôpitalPitié-Salpêtrière, Paris FRANCE
Contact Information: Phone: +33 1 42 17 80 37 e-mail: [email protected]
Requested Patient Involvement: Patients and treating doctors are encouraged to contact Prof. Julien Haroche for more information.
ClinicalTrials.gov Identifier: NCT02089724